Catalyst is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating neuromuscular and neurological diseases.
At Catalyst, we utilize leading-edge science in search of therapies that will improve the lives of those who suffer from rare-diseases, often without any therapeutic options. We believe that no other field of medicine holds as much promise and makes such a significant impact on patents’ lives as the development of novel orphan drugs.
- Passion is our commitment to engage, energize and inspire others and ourselves
- Trust is our commitment to live an authentic life, with sincerity and honesty in all endeavors
- Integrity is our commitment to the highest ethical standards, to lead with principles and to expect the very best from our employees and our company
These attributes guide every decision and action we make, as individuals and, collectively, as Catalyst Pharmaceuticals.
Catalyst has launched amifampridine, the only evidence-based, FDA-approved treatment for adult patients with Lambert-Eaton Myasthenic Syndrome (LEMS), it’s the first product approved by the FDA for LEMS in more than 35 years.
Catalyst has successfully completed 2 phase 3, multicentered clinical trials of amifampridine in patients with LEMS and is conducting a separate clinical trial in patients with congenital myasthenic syndromes (CMS). Catalyst is preparing to launch an additional trial examining the efficacy and safety of amifampridine in patients with MuSK-positive myasthenia gravis (MuSK-MG).
Catalyst is also developing the highly potent GABA-aminotransferase (GABA-AT) inhibitor, CPP-115, for the treatment of infantile spasms, a rare form of debilitating epileptic seizures that presents in infants.